General
Preferred name
KD019
Synonyms
TESEVATINIB ()
P&D ID
PD049475
CAS
781613-23-8
Tags
drug candidate
Drug indication
Polycystic kidney disease
Meningioma metastases
Recurrent glioblastoma
Non-small-cell lung cancer
Brain metastases
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tesevatinib (XL-647) is an orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with broad spectrum activity againt EGFRs and VEGFRs , and which has pre-clinical antineoplastic potential . The two CAS numbers associated with this compound (781613-23-8 and 651031-01-5) indicate a third chiral centre, however the structure shown here does not specify stereochemistry at this point. (GtoPdb)
Compound Sets
6
Concise Guide to Pharmacology 2017/18
7944
Concise Guide to Pharmacology 2019/20
7944
Concise Guide to Pharmacology 2021/22
7944
Concise Guide to Pharmacology 2023/24
7944
DrugMAP
DMEFW3G
Guide to Pharmacology
7944
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
490.13
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
3
cLogP
5.79
TPSA
59.51
Fraction CSP3
0.42
Chiral centers
3.0
Largest ring
6.0
QED
0.44
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Source data